STCube

STCube Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of STCube (052020.KQ) as of Oct 24, 2026 is 3.32. In the previous year, Net Debt to Free Cash Flow Ratio was 1.33 — a change of 150.60% (higher).

Net Debt/FCF

3.32

YoY

150.60%

Last updated:

Net Debt to Free Cash Flow Ratio of STCube is 2024 3.32 . Net Debt to Free Cash Flow Ratio of STCube was 2023 1.33 . It decreases by 150.60% higher compared to the previous year.

The STCube Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
0.61 KRW
Jan 1, 2018
4.90 KRW
Jan 1, 2019
21.62 KRW
Jan 1, 2020
-0.50 KRW
Jan 1, 2021
0.89 KRW
Jan 1, 2022
3.06 KRW
Jan 1, 2023
1.33 KRW
Jan 1, 2024
3.32 KRW
The STCube Net Debt/FCF history
YEARNet Debt/FCFYoY
3.32+150.60%
1.33-56.75%
3.06+244.03%
0.89-279.10%
-0.50-102.30%
21.62+340.69%
4.90+708.36%
0.61-97.81%
27.66+2,912.24%
0.92—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Net Debt to Free Cash Flow Ratio of STCube is 3.32 in 2024.

Net Debt to Free Cash Flow Ratio of STCube changed from 1.33 to 3.32, representing a 150.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio STCube since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's STCube with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — STCube

All Key Metrics — STCube